Phil Johnson is the founder of Interius BioTherapeutics. Interius BioTherapeutics has raised $76M in total funding. Latest round: Series A.
Phil Johnson is the CEO of Interius BioTherapeutics, a preclinical stage gene therapy company. The company is developing a platform for in vivo cell-specific gene delivery, initially focused on treating hematologic malignancies by generating CAR T cells directly in vivo. Interius BioTherapeutics has raised $76 million in a Series A financing round.
Full founder directory · Investor directory · Company funding database · Fundraising library